SyB L1101 / SyB C-1101 *SyB L1101: injection / SyB C-1101: oral
SyB L-1101 (injection)/SyB C-1101 (oral) (generic name: Rigosertib Sodium) is an anticancer agent with a unique multikinase inhibitory action (it causes cancer cells to die by inhibiting multiple kinases involved in cancer cell growth, invasion and metastasis). It is currently being developed by Onconova Therapeutics, Inc. (Headquarters: Pennsylvania, USA; "Onconova") for the treatment of myelodysplastic syndrome (MDS) and solid tumors in the United States and Europe.
SymBio In July 2011, Seiyaku entered into a license agreement with Onconova for the exclusive rights to develop and commercialize the drug in Japan and South Korea, and is currently developing an injection formulation for the indication of relapsed/refractory high-risk MDS and a transfusion-dependent, low-risk MDS (in combination with azacitidine). We are currently developing an oral formulation for the indication of high-risk MDS (in combination with azacitidine) and transfusion-dependent low-risk MDS.
In the future, based on the progress of clinical trials overseas, we will also expand the indication to solid tumors.
Myelodysplastic Syndrome (MDS)
Myelodysplastic syndrome (MDS) is a pre-condition of malignant transformation of blood cells, and the number of patients has been increasing in recent years. It is one of the therapeutic areas with extremely high medical needs due to the lack of excellent therapeutic drugs.